EFA – Personalised approach to severe asthma explained at Innovative Medicines Initiative event
President Breda Flood of the European Federation of Allergy and Airways Diseases Patients’ Association (EFA), recently spoke about ‘a personalised approach to severe asthma’ at a workshop on ‘applying open innovation to bring personalised medicine to new disease areas’ organised by the Innovative Medicines Initiative (IMI).
EFA highlighted the fact that there is still not a good enough understanding of the different phenotypes within the severe asthma population. This means many people do not have precise enough diagnosis and there are not effective enough treatments for them with no possibility for a truly individual management plan.
Severe asthma is not a single disease and we have to take in account that individual patients are clinically very different. The U-BIOPRED project which aims to speed up the development of better treatments for patients with severe asthma uses a sophisticated and novel integrated “systems medicine” approach to help characterise patients with different types of severe asthma more precisely.
All three speakers at the IMI workshop spoke about their involvement in the project from their own perspective. President Flood an asthma patient herself, explained how EFA continues to provide the perspective from patients living with severe asthma.
Originally posted on 11 April 2014